Ahmad Tarhini, MD, PhD, director, Cutaneous Clinical and Translational Research, leader, Neoadjuvant and Adjuvant Translational Science Program, senior member, Moffitt Cancer Center, Research Institute Departments of Cutaneous Oncology and Immunology; professor, Oncologic Sciences, the University of South Florida Morsani College of Medicine; chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN); chair, ORIEN ImmunoOncology Research Subcommittee, discusses the rationale for investigating high-dose bolus interleukin-2 (IL-2) plus concurrent low-dose ipilimumab (Yervoy), followed sequentially by nivolumab (Opdivo), in patients with advanced melanoma.
Health Professionals
Gene activity predicts severe side effects from melanoma immunotherapy
Adverse effects from immunotherapy treatment in melanoma patients are associated with a distinct pattern of
gene expression, offering the possibility for improved therapeutic strategies.
Beyond the slip and slop for keratinocyte skin cancer
For patients with a high burden of non-melanoma cancers, there is more to prevention than just sun avoidance and regular checks and excisions.
Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.